Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E4 Carriers.

NCT00575055 is registered in ClinicalTrials.gov with JANSSEN Alzheimer Immunotherapy Research & Development, LLC as lead sponsor.

NCT NCT00575055
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00575055 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E4 Carriers.
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2007
Completion date
April 30, 2012
Enrollment
1,121 (actual)
Sites
186

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease